Ketamine for Veterans: What the Research Shows

Veterans face disproportionately high rates of PTSD, treatment-resistant depression, and suicidal ideation. Standard treatments, including SSRIs and prolonged exposure therapy, help many but leave a significant number without adequate relief. Ketamine has emerged as a promising option for this underserved population, and two recent studies provide meaningful data on its efficacy in military and veteran communities.

The 2024 Frontiers Meta-Analysis

A 2024 meta-analysis published in Frontiers in Psychiatry pooled data from multiple studies examining ketamine's effects on PTSD symptoms in veteran and military populations. The analysis aggregated results across different administration routes and treatment protocols to assess the overall evidence base.

Key Findings

The meta-analysis found a significant overall effect of ketamine on PTSD symptom reduction in military populations. Several specific findings stood out:

• Rapid symptom relief: Consistent with the broader ketamine literature, veterans showed meaningful reductions in PTSD symptoms within 24 hours of treatment. This rapid onset is particularly relevant for veterans in crisis or those experiencing acute suicidal ideation.
• Effect on intrusive symptoms: Ketamine showed particular efficacy for intrusive symptoms, the flashbacks, nightmares, and involuntary re-experiencing that many veterans identify as the most disruptive aspects of PTSD.
• Comorbid depression improvement: Veterans with co-occurring PTSD and depression showed improvements in both conditions simultaneously, reflecting ketamine's broad action on shared neural circuits.
• Tolerability: Side effect profiles in veteran populations were consistent with those observed in civilian studies, with transient dissociation and mild hemodynamic changes being the most common.

The meta-analysis noted that while the evidence is promising, the total number of randomized controlled trials specifically focused on veterans remains limited, and larger, multi-site trials are needed.

The 2026 JMVFH Retrospective Report

A 2026 retrospective report published in the Journal of Military, Veteran, and Family Health (JMVFH) examined real-world outcomes from a program combining sublingual ketamine with an intensive outpatient program (IOP) for veterans with PTSD and depression.

The Treatment Model

The program delivered sublingual ketamine in a structured outpatient setting, combined with group and individual therapy, psychoeducation, and peer support. This model is significant because it moves beyond the infusion clinic paradigm to a more accessible and holistic treatment framework.

Veterans received sublingual ketamine at scheduled intervals throughout their IOP enrollment, with therapy sessions timed to capitalize on the neuroplasticity window following each dose. The integration of ketamine into a comprehensive treatment program, rather than offering it as a standalone intervention, reflects the growing understanding that ketamine works best as part of a broader therapeutic approach.

Results

The retrospective analysis reported clinically meaningful improvements across multiple outcome measures:

• PTSD symptom reduction: Veterans showed significant decreases in PCL-5 scores (the standard PTSD checklist) from intake to discharge.
• Depression improvement: PHQ-9 depression scores decreased substantially, with many veterans moving from the moderate-severe range to the mild range or below.
• Functional gains: Beyond symptom scores, veterans reported improvements in daily functioning, sleep quality, and interpersonal relationships.
• Treatment engagement: The sublingual route and outpatient format were associated with high treatment completion rates, suggesting this model is practical and acceptable to veteran populations.

Why Veterans Need Better Options

The urgency of this research cannot be overstated. Veterans experience PTSD at rates roughly three times higher than the general population. Veteran suicide remains a national crisis, with approximately 17 veterans dying by suicide each day in the United States. Many veterans who seek help through the VA system face long wait times and are prescribed medications that may take weeks to work, if they work at all.

Ketamine's rapid onset of action makes it uniquely suited to address the acute needs of veterans in crisis. The ability to produce meaningful symptom relief within hours, rather than weeks, could be life-saving for veterans experiencing suicidal ideation.

Access Considerations

Access remains a significant barrier. Many veterans live in rural areas far from ketamine infusion clinics, and VA coverage for ketamine therapy varies. The JMVFH report's focus on sublingual ketamine is encouraging because it demonstrates efficacy with a route of administration that can be delivered in at-home and telehealth settings.

For veterans interested in exploring ketamine therapy, several pathways exist:

• At-home treatment programs like Isha Health that offer physician-led sublingual ketamine therapy via telehealth
• Coordination with existing VA care, as ketamine can complement ongoing therapy and medication management
• Community-based intensive outpatient programs that incorporate ketamine into comprehensive treatment plans

What Isha Health Offers Veterans

Isha Health's clinical outcomes demonstrate strong results across conditions common in veteran populations, including PTSD, treatment-resistant depression, and anxiety. Our telehealth model eliminates geographic barriers, making treatment accessible to veterans regardless of their proximity to specialty clinics.

The Bottom Line

The combined evidence from the 2024 meta-analysis and the 2026 JMVFH retrospective report supports ketamine as an effective treatment option for veterans with PTSD and depression. The data is particularly encouraging for sublingual ketamine combined with structured therapeutic programs, a model that can be delivered accessibly and at scale.

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.